DL-去甲肾上腺素盐酸盐, 98%|DL-Norepinephrine Hydrochloride|cas:55-27-6|西域试剂

DL-去甲肾上腺素盐酸盐, 98%,DL-Norepinephrine Hydrochloride

产品编号：西域试剂-WR120692| CAS NO：55-27-6| MDL NO：MFCD00012880| 分子式：(HO)₂C₆H₃CH(OH)CH₂NH₂ · HCl| 分子量：205.64

DL-Norepinephrine hydrochloride 是模拟内源性去甲肾上腺素的拟交感神经作用的合成苯乙胺。DL-Norepinephrine hydrochloride 是一种靶向 α1 adrenoceptor 和 β1 adrenoceptor 的神经递质，可降低心内膜下氧分压。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
西域试剂-WR120692	￥165.00	杭州北京（现货）
西域试剂-WR120692	￥625.00	杭州北京（现货）
西域试剂-WR120692	￥2256.00	杭州北京（现货）
西域试剂-WR120692	￥6913.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

英文名称

DL-Norepinephrine Hydrochloride

CAS编号

55-27-6

产品描述

产品熔点

140-144ºC (dec.)

产品沸点

442.6ºC at 760mmHg

产品密度

1.397g/cm3

产品闪点

221.5ºC

精确质量

205.050568

PSA

86.71000

LogP

1.59220

外观性状

crystalline | off-white to tan

溶解性数据

In Vitro:

1M HCl : 100 mg/mL (486.29 mM; ultrasonic and adjust pH to 1 with HCl)

DMSO : 50 mg/mL (243.14 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.8629 mL	24.3143 mL	48.6287 mL
5 mM	0.9726 mL	4.8629 mL	9.7257 mL
10 mM	0.4863 mL	2.4314 mL	4.8629 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 0.89 mg/mL (4.33 mM); Clear solution

此方案可获得 ≥ 0.89 mg/mL (4.33 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 8.9 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 0.89 mg/mL (4.33 mM); Clear solution

此方案可获得 ≥ 0.89 mg/mL (4.33 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 8.9 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 0.89 mg/mL (4.33 mM); Clear solution

此方案可获得 ≥ 0.89 mg/mL (4.33 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 8.9 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

靶点

IC50: α1 adrenoceptor and β1 adrenoceptor

储存条件

2-8°C

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品

符号	GHS06
信号词	Danger
危害声明	H301
警示性声明	P301 + P310
个人防护装备	Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
危害码 (欧洲)	T
风险声明 (欧洲)	R25
安全声明 (欧洲)	36/37/39-45
危险品运输编码	UN 2811
WGK德国	3
RTECS号	DN6650000
包装等级	III
危险类别	6.1(b)
海关编码	2922509090

Name:	DL-Norepinephrine Hydrochloride 99% Material Safety Data Sheet
Synonym:
CAS:	55-27-6

Section 1 - Chemical Product MSDS Name:DL-Norepinephrine Hydrochloride 99% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
55-27-6	DL-Norepinephrine Hydrochloride	99	200-229-8

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

Section 3 - HAZARDS IDENTIFICATION

EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
The toxicological properties of this substance have not been fully investigated. Inhalation of dust may cause respiratory tract irritation.
Chronic:
No information found.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use only in a well-ventilated area.
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 55-27-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 145.00 - 147.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H11NO3.HCl
Molecular Weight: 205.64

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stability unknown.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 55-27-6: DN6650000 LD50/LC50:
Not available.
Carcinogenicity:
DL-Norepinephrine Hydrochloride - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

Section 12 - ECOLOGICAL INFORMATION

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: ALKALOID SALTS, SOLID, N.O.S.*
Hazard Class: 6.1
UN Number: 1544
Packing Group: III
IMO
Shipping Name: ALKALOIDS, SOLID, N.O.S.
Hazard Class: 6.1
UN Number: 1544
Packing Group: III
RID/ADR
Shipping Name: ALKALOID SALTS, SOLID, N.O.S.
Hazard Class: 6.1
UN Number: 1544
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 55-27-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 55-27-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 55-27-6 is not listed on the TSCA inventory.
It is for research and development use only.

SECTION 16 - ADDITIONAL INFORMATION
N/A

1207201-66-8

~99%

55-27-6

文献：Bernini, Roberta; Crisante, Fernanda; Barontini, Maurizio; Fabrizi, Giancarlo Synthesis, 2009 , # 22 art. no. P09409SS, p. 3838 - 3842

5090-29-9

~95%

55-27-6

文献：NEON LABORATORIES LTD.; DALVI, Mahesh Bhagoji; KENNY, Rajesh Shashikant; KAWLE, Ganesh Ramachandra Patent: WO2013/8247 A1, 2013 ; Location in patent: Page/Page column 10 ;

[1]. Matsuda H, et al. Effects of nitroglycerin, adenosine, noradrenaline, and isoproterenol on the myocardial oxygen tension. Jpn Heart J. 1979 Nov;20(6):867-79.